Our work spans software development to biological assays of neurotoxicity. We have active programs investigating protein dynamics, folding and misfolding, particularly as related to human mutations and various diseases. We have developed a molecular modeling and simulation package, which we have used to simulate the native state dynamics and unfolding/folding of representatives of essentially all known protein folds (95%) in an effort we refer to as Dynameomics. Novel databases and mining methods are being developed for this large dataset (hundreds of terabytes) comprising the largest collection of protein simulations and structures in the world. We are using this resource to develop tools for protein modeling and design. These tools and associated simulations are already being used to design diagnostic and therapeutic agents for amyloid diseases. The computational designs have been synthesized and are being tested in four different amyloid systems: transthyretin (systemic amyloidosis), Abeta (Alzheimer’s Disease), amylin (type 2 diabetes) and the prion protein (transmissible spongiform encephalopathies). And, in very recent studies, these designed compounds are also being tested for their ability to block bacterial biofilm formation.